PR Newswire PharmaOriginal article
Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
RegulatoryapprovedLUMVOAPositive
AI Analysis
Summary
Viridian's LUMVOA has received recent approval for Graves' ophthalmopathy, expected to drive market growth at a CAGR of 9% through 2036 as disease awareness and earlier diagnosis improve.
Outcome Details
LUMVOA approved for Graves' ophthalmopathy
Importance:5/10
Sentiment:
0.60
Graves' ophthalmopathyautoimmunemarket analysisFDA approvalLUMVOA
Related Companies
Read the original article
Published by PR Newswire Pharma on July 29, 2026 2:31 PM